FDA-approved clinical trial of Stem Cell Educator therapy has started in the United States

Stem Cell Educator (SCE) therapy, developed and patented by the Dr. Yong Zhao, uses Cord Blood Stem Cells to “educate” autologous immune cells, reversing autoimmunity in patients with Type 1 Diabetes (T1D) and providing lasting improvement of C-peptide levels, reduced median glycated hemoglobin A1C (HbA1C) values, and decreased median daily usage of insulin. SCE has been proven safe and effective in Chinese and Spanish subjects for the improvement of T1D and other autoimmune diseases. FDA approved the Phase I/II clinical trial of Stem Cell Educator therapy for the treatment of T1D. This clinical has been started at Hackensack University Medical Center, the biggest hospital in New Jersey and top 3 in New York metropolitan area. For more information, please visit HackensackUMC with Study ID# Pro00006262.